Mitsubishi Tanabe Pharma America Inc (MTPA) announced on Tuesday that Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation (MTPC), its parent company, has entered into a strategic research collaboration with US biotechnology company Dewpoint Therapeutics Inc.

The partnership is aimed at developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.

Under the agreement MTPC will pay Dewpoint an upfront payment and, upon reaching certain pre-specified milestones, MTPC will have the exclusive option to license the programme and assume responsibility for global clinical development and commercialisation.

Yasutoshi Kawakami, MTPA president, said: "ALS remains one of the most challenging diseases to treat, with limited treatment options for patients. Through this collaboration with Dewpoint Therapeutics, we hope to advance innovative approaches to address this devastating disease by leveraging their expertise in condensate biology. Together, we are committed to making a meaningful difference for patients living with ALS."